The study is based on the constitution of a collection of tumor and blood samples for the development of tumoroid for functional tests to predict clinical response to treatment.
Patient with undifferentiated primary carcinoma (UPC) with histological and immunohistochemical evidence, validated in a local and/or national UPC multidisciplinary consultation
Patient with indication for systemic 1st-line treatment at the time of inclusion. Treatment may already have begun at the time of inclusion, but within the limit of 2 treatment cycles administered.
Patient with life expectancy greater than 3 months
Patient of legal age
Persons deprived of their liberty or under guardianship (including curatorship)
Pregnant or breast-feeding patient
Patient with undifferentiated primary carcinoma (UPC) with indication for 1st-line treatment
Cohort
Prospective
organoid etablishment
Other interventionPrior to initiation of 1st-line therapy: * Collection of an additional study-specific tumor sample for tumoroid analysis (1 fresh tumor sample) * A blood test blood a for tumoroid realization and : * Analysis of ex vivo tumoroid response to treatment and correlation with patient response in vivo * Analysis of correlation between in vivo and ex vivo tumor characteristics * Analysis of first- and second-line survival rates and overall survival
Rate of establishment of exploitable tumor organoids
Rate of establishment usable tumor organoids for predictive tests of response to treatment.
Click on the lead sponsor to view all of their trials.
